Betterise Health Tech

What Betterise Health Tech does

Betterise Health Tech (legal entity: BETTERISE Technologies) is a French digital therapeutics company founded in 2013, headquartered in Biarritz with operations in Levallois-Perret. The company developed a tele-surveillance and clinical decision support platform called Theraflow, powered by its proprietary BQL (Betterise Query Language) indexing system that processes over 3,000 patient criteria per patient. Its CE Class IIa certified medical device portfolio centers on Resilience PRO (formerly Oncolaxy) for remote cancer patient monitoring across all tumor types, and Cardiolaxy for heart failure decompensation detection. The platform collects patient-reported outcomes via weekly SMS questionnaires in 15+ languages, applies CE-marked algorithms for anomaly detection, and integrates with hospital information systems (DPI). An additional product pipeline includes Uroconnect for post-surgical urology follow-up (Class I, in development), plus consumer health offerings such as Betterise Diabète and the #MBM pregnancy app (formerly TOP 3 health app).

Betterise operated a B2B enterprise sales motion targeting hospitals, cancer centers, and cardiology departments, with products reimbursed by French national health insurance (Assurance Maladie) under tele-surveillance regulations effective January 2022. The company also generated revenue through pharmaceutical and laboratory distribution partnerships and corporate primary prevention services. The company served over 500,000 patients since 2013 and was deployed in approximately 20 healthcare establishments across France and Germany. On November 9, 2021, Betterise was acquired by Resilience, a digital health company co-developed with Gustave Roussy, making it a subsidiary of the Resilience group focused on oncology care pathway transformation. Prior to acquisition, Betterise was profitable with revenue exceeding €2 million, operating with 11-50 employees under co-founder and President Paul-Louis Belletante.

Name

Betterise Health Tech

Legal name

BETTERISE Technologies

Website

https://betterise-healthtech.com

Company type

Private

Founded year

2013

Operating status

Acquired

Headcount range

11–50 employees

Short description

Betterise Health Tech is a French digital therapeutics company (founded 2013, acquired by Resilience in 2021) that develops CE Class IIa certified tele-surveillance software for oncology and cardiology, serving hospitals across France and Germany with its Theraflow platform and proprietary BQL technology.

Ownership category

akta.pro rank

Product category

Digital Health Medical Software

NAICS

All Other Outpatient Care Centers (621498)

SIC

Services-Health Services (8000), Services-Home Health Care Services (8082)

akta.pro primary industry

Oncology Remote Symptom Monitoring & Care Navigation (HLALAFAD)

akta.pro secondary industries

Oncology Telemedicine Platforms (HLALAGAH), Cardiology Telemedicine Platforms (HLALAGAB), Virtual Specialty Care Platforms (tele-stroke, tele-ICU, tele-derm, tele-cardiology) (HLALABAD)

Keywords

• Digital therapeutics
• Remote patient monitoring
• Tele-surveillance software
• Clinical decision support
• Medical device software

Headquarters

HQ city

Levallois-perret

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Healthcare institution licensing: Digital medical device software licensed to hospitals and healthcare establishments for remote patient monitoring. Products are Class IIa CE marked medical devices reimbursed by French national health insurance (Assurance Maladie).
2. Enterprise digital health services: Digital therapeutic and prevention services for pharmaceutical companies and large corporations, including primary prevention services (Betterise.me) and disease-specific programs.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Betterise Health Tech develops and licenses CE-marked Class IIa medical device software for tele-surveillance and clinical decision support, enabling remote patient monitoring for oncology and cardiology providers. Its Theraflow platform, powered by proprietary BQL (Betterise Query Language), processes over 3,000 patient criteria per patient to assist care teams in detecting relapses, complications from therapies, and therapeutic toxicities through weekly SMS-based symptom reporting and adaptive patient education content.

Product overview

Betterise Health Tech (now part of Resilience) is a digital therapeutics company offering a modular platform with specialized medical software products. The core technology is Theraflow, a next-generation telemonitoring platform powered by the proprietary Betterise Query Language (BQL). The product portfolio centers on Resilience PRO (formerly Oncolaxy) for comprehensive oncology telemonitoring across all cancer types, and Cardiolaxy for cardiology remote patient monitoring and clinical decision support. Additional offerings include Uroconnect for post-surgical urology follow-up, Betterise Diabète for diabetes management, Betterise.me for primary prevention, and the #MBM pregnancy companion app. All clinical products are CE-marked medical devices with varying regulatory classifications.

Differentiator

Problem solved

Functional benefit

Brands

• Resilience PRO: Class IIa medical device for remote cancer patient monitoring, follow-up, relapse detection, and therapeutic education. Indicated for all cancer types.
• Oncolaxy
• Cardiolaxy
• Uroconnect

Products and services

• Resilience PRO CE Class IIa medical device software for remote cancer patient surveillance, follow-up, relapse detection, therapeutic education, and clinical decision support indicated for all cancer types; designed for hospitals and oncology centers.
• Cardiolaxy CE Class IIa certified remote monitoring and clinical decision support software for cardiology, enabling remote detection of decompensations in heart failure patients through biomedical dynamic analysis; for cardiology departments and heart failure treatment centers.
• Oncolaxy CE Class IIa medical device providing remote therapeutic management software for cancer patients, enabling automatic detection of relapses or therapy-related complications through symptom evolution analysis; for oncology healthcare providers.
• Betterise Diabète Therapeutic accompaniment and monitoring service for Type 1 and Type 2 diabetic patients, available on iOS and Android with worldwide distribution.
• Betterise.me Primary prevention digital health service providing general health and wellness guidance; commissioned by large companies for employee wellness and prevention programs.
• #MBM (Moi, Bientôt Maman)

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• ResiliencecoreStrategic or Co-development Partner · 9 November 2021Acquisition of Betterise by Resilience (November 9, 2021). Resilience is a digital health company dedicated to cancer patient monitoring, co-designed with Gustave Roussy. Integration of Betterise's tele-surveillance technology into Resilience's platform.
• CHU de BordeauxcoreStrategic or Co-development Partner · 1 January 2019Research partnership with CHU de Bordeaux, Service des Maladies Coronaires et Vasculaires, for the implementation of Therapeutic Support & Tele-monitoring services in cardiology. Professor Thierry Couffinhal (PU-PH, Director UMR Inserm U1034) leads the collaboration.
• UNICANCERcoreStrategic or Co-development Partner · 1 January 2018Collaboration with UNICANCER for the development of ePRO (Patient Reported Outcomes) services in oncology, contributing to the CAPRI study and digital therapeutic solutions.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Noona Healthcare: Patient engagement platform specifically designed for oncology symptom reporting and PROs; directly competes in oncology remote symptom monitoring with Betterise/Resilience PRO.
• Kaiku Health: Finnish oncology digital therapeutics platform offering patient-reported outcomes and symptom monitoring; acquired by Elekta in 2021. Closely comparable to Resilience PRO/Oncolaxy in oncology telemonitoring.
• Implicity: French remote cardiac monitoring platform for heart failure and arrhythmia patients. Directly comparable to Cardiolaxy's cardiology remote monitoring and clinical decision support offering, with similar French hospital customers.
• Voluntis (Aptarion): French digital therapeutics company developing CE-marked patient-facing software for oncology and chronic disease; directly comparable in regulatory pathway, oncology focus, and French reimbursement context.
• Cureety: French oncology digital therapeutics startup offering remote monitoring and patient-reported outcomes for cancer patients undergoing treatment; very close peer to Resilience PRO in oncology indication and French market.
• Huma (formerly Medopad): Digital health platform providing remote patient monitoring, virtual wards, and decentralized clinical trials; overlaps with Theraflow's RPM and clinical decision support capabilities across multiple therapy areas.

Broad incumbents

• Omada Health: Established US digital therapeutics company focused on chronic disease prevention and management (diabetes, hypertension). Comparable business model (digital therapeutic RPM reimbursed via payer/B2B channels) but operates at much larger scale.
• ResMed (Propeller Health): Global leader in respiratory and connected health RPM through Propeller Health; broader incumbent with overlapping chronic disease remote monitoring capabilities across therapeutic areas.
• Hinge Health: Large-scale digital therapeutics platform for musculoskeletal care; comparable in delivering CE/FDA-style cleared digital therapeutic interventions reimbursed through enterprise/B2B channels, though focused on MSK rather than oncology/cardiology.

Regional players

• Withings: French connected health device manufacturer with health monitoring solutions (Blood Pressure Monitor, Sleep Analyzer, etc.). An adjacent European player in remote patient monitoring data capture, complementary rather than directly competing in clinical-grade oncology/cardiology RPM.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Betterise Health Tech